# Mini-bioreactors for DOE screening Automated mini- and micro-bioreactors (1-250 mL) running 24-48 cultures in parallel that map a bioprocess Design Space in days rather than months — the high-throughput on-ramp to cell-line, strain and upstream-process development, led by the German ambr, BioLector and DASbox platforms. Source: https://en.bioecon.ru/technology/mini-bioreactors-doe-screening/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: FDA Process Validation Stage 1 & ICH Q8 Design Space | OECD: Industrial biotech | Regulator: FDA (USA), EMA (EU), NMPA (China)] Mini-bioreactors for Design-of-Experiments (DOE) screening are the high-throughput on-ramp to bioprocess development: small (1-250 mL) parallel bioreactors that run 24 to 48 cultures simultaneously under individually controlled pH, dissolved oxygen and feed conditions, replacing the slow shake-flask era. The dominant platform is Sartorius's ambr, a disposable 24- or 48-vessel automated system that delivers comparable performance to benchtop bioreactors at roughly 1/100th the volume and a tenth of the time, so a cell-line or clone screen that once took months now closes in days. m2p-labs' BioLector adds shaken microtiter-plate screening with online OD, pH, DO and fluorescence monitoring, and Eppendorf's DASbox provides four to 24 fully controlled 60 mL benchtop mini-bioreactors. Together these tools let developers map the ICH Q8 Design Space — the multidimensional envelope of acceptable process parameters — early, feeding scale-up models that satisfy FDA Stage 1 process validation. The market is concentrated in a handful of European platforms that have become standard equipment in every major biopharma and industrial-biotech process-development group. The key directions of mini-bioreactors and DOE screening are: 1. **Automated parallel mini-bioreactors (Automated Parallel Mini-Bioreactors):** 24-48 disposable vessels with integrated liquid handling for automated inoculation, feeding and sampling — Sartorius ambr 15/250, the cell-culture and microbial workhorses. 2. **Online-monitored micro-bioreactor plates (Online-Monitored Micro-Plates):** shaken microtiter plates with online biomass, pH, DO and fluorescence readouts for high-density microbial strain screening — m2p-labs BioLector. 3. **Benchtop controlled mini-bioreactors (Benchtop Mini-Bioreactors):** four to 24 individually controlled 60 mL vessels giving true bioreactor control at small scale — Eppendorf DASbox, Applikon MiniBio. 4. **DOE design-space mapping (DOE Design-Space Mapping):** statistically designed experiment matrices that, run across these platforms, define the ICH Q8 Design Space and de-risk scale-up to pilot and GMP scale. ### Sectoral value chain ``` [DOE design] ──> [parallel mini-bioreactor run] ──> [online analytics + sampling] ──> [data model] │ (ICH Q8 Design Space) │ ▼ [scale-up] <─── [lead-clone / condition selection] <─────┘ ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **DOE Design** | statistical experiment matrix over the process parameters | **In:** process goals, parameters. **Out:** design matrix. | | **Parallel Mini-Bioreactor Run** | 24-48 vessels run under individual control | **In:** clones/strains, media, design matrix. **Out:** parallel cultures. | | **Online Analytics & Sampling** | online OD/pH/DO + automated at-line titer sampling | **In:** cultures, sensors, autosampler. **Out:** time-course data. | | **Data Model** | multivariate model of the Design Space | **In:** time-course data. **Out:** response surface, lead conditions. | | **Lead Selection** | clone/strain and condition ranking | **In:** response surface. **Out:** lead clone, setpoints. | | **Scale-Up** | transfer of setpoints to pilot/GMP bioreactors | **In:** lead clone, setpoints. **Out:** scaled process. | Cross-cutting technologies of the sector: - **Disposable mini-vessel formats (Disposable Mini-Vessels):** single-use stirred or bubbled 10-250 mL vessels that eliminate cleaning and cross-contamination between DOE runs. - **Integrated liquid handling (Integrated Liquid Handling):** onboard robotics for inoculation, feed addition and automated sampling into HPLC/at-line analytics (Hamilton, Tecan integration). - **Scale-down modelling (Scale-Down Modelling):** matching mini-bioreactor mixing, kLa and power-input to pilot scale so DOE results transfer reliably. --- ## US The United States is the largest market for mini-bioreactor DOE platforms — every major biopharma and CDMO process-development group runs ambr and DASbox fleets — and supplies the automation and analytics integrated around them. ### automation integration, process-validation driver, CDMO fleets - **Hamilton Company:** the Reno-based automation and sensor maker provides the precision liquid handling, sensors and integrated robotics that many mini-bioreactor DOE workflows pipe into for sampling and feed delivery. - **Process-validation driver:** FDA Process Validation Stage 1 (process design) and ICH Q8 Design-Space expectations push US biopharma to characterise the design space early with parallel mini-bioreactor DOE. - **CDMO fleets:** US CDMOs operate dense fleets of ambr and DASbox systems to run client clone screens and process characterisation at throughput. --- ## CN China's biopharma and industrial-biotech process-development groups have adopted the leading mini-bioreactor DOE platforms rapidly, while domestic bioreactor makers serve the broader upstream market. ### platform adoption, strain-development demand, domestic makers - **Platform adoption:** Chinese biologics and CDMO groups (WuXi, Innovent, Legend) run ambr, DASbox and BioLector fleets for cell-line and strain screening, aligned with NMPA process-validation expectations. - **Strain-development demand:** China's industrial-biotech and synthetic-biology build-out drives strong demand for microbial DOE screening (BioLector, DASGIP) for strain engineering. - **Domestic makers:** local bioreactor manufacturers serve the conventional upstream market; the high-throughput DOE-platform segment remains led by the European platforms. --- ## EU Europe authors the mini-bioreactor DOE category: three of the four leading platforms are German, with the fourth from the Netherlands. ### ambr (Sartorius), BioLector (m2p-labs), DASbox (Eppendorf) - **Sartorius (Germany):** the ambr 15 and ambr 250 automated mini-bioreactor systems run 24-48 disposable vessels with integrated liquid handling, the reference platform for cell-line and upstream-process DOE in cell-culture and microbial applications. - **m2p-labs (Germany):** the BioLector platform screens shaken microtiter plates with online OD, pH, DO and fluorescence monitoring, optimised for high-throughput microbial strain and media screening. - **Eppendorf (Germany):** the DASbox mini-bioreactor system provides four or 24 fully controlled 60 mL vessels, with the DASGIP parallel-bioreactor line for the next scale step. - **Applikon Biotechnology (Netherlands, Getinge):** the MiniBio benchtop mini-bioreactor and my-Control controller add a flexible individually-controlled parallel option. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Sartorius** | 🇩🇪 Germany | *ambr 15 / ambr 250* | 24-48 disposable vessels, integrated liquid handling | Commercial | | **m2p-labs** | 🇩🇪 Germany | *BioLector (microtiter)* | online OD/pH/DO/fluorescence, microbial screening | Commercial | | **Eppendorf** | 🇩🇪 Germany | *DASbox, DASGIP* | 4-24 controlled 60 mL vessels | Commercial | | **Applikon Biotechnology** | 🇳🇱 Netherlands | *MiniBio, my-Control* | benchtop controlled mini-bioreactor (Getinge) | Commercial | | **Hamilton Company** | 🇺🇸 USA | *liquid handling, sensors, robotics* | DOE sampling/feed automation integration | Commercial | --- ## Tech stack and innovations The mini-bioreactor DOE stack rests on parallel small-volume control, rich online analytics and statistical design, each generation widening how much of the design space a single week can cover. 1. **Automated parallel mini-vessels (Automated Parallel Vessels):** - 24-48 disposable 10-250 mL vessels are run in parallel under individual pH, temperature and DO control with integrated robotic inoculation, feeding and sampling. - case: Sartorius ambr 250 delivers cell-culture performance comparable to benchtop reactors at ~100-1000x less volume per vessel. 2. **Online microtiter monitoring (Online Microtiter Monitoring):** - shaken microtiter plates are read non-invasively for biomass (OD), pH, DO and fluorescence, enabling hundreds of microbial conditions per run. - m2p-labs BioLector pairs this with microfluidic feeding (BioLector Pro) for fed-batch screening. 3. **DOE design-space modelling (DOE Design-Space Modelling):** - statistical design matrices (definitive screening, response-surface) are run across the platforms to map the ICH Q8 Design Space and rank clones/conditions. - multivariate models transfer setpoints to pilot and GMP scale via matched kLa and power-input scale-down. --- ## Value chains and production pipelines ### Industrial pipeline of a DOE screening campaign (FDA Stage 1 / ICH Q8) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. DOE design │ ───> │ 2. Parallel mini-bio run │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Lead selection │ <─── │ 3. Online analytics + model│ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Scale-down validation │ ───> │ 6. GMP transfer │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: DOE design A statistical design matrix (definitive-screening or response-surface) is built over the process parameters — media, feed, temperature, pH, DO — across the clone or strain panel. #### Stage 2: Parallel mini-bioreactor run The matrix is executed on 24-48 disposable mini-vessels (ambr) or online-monitored microtiter plates (BioLector), each vessel under individual control with automated inoculation and feeding. #### Stage 3: Online analytics and modelling Online OD/pH/DO and automated at-line titer sampling feed a multivariate response-surface model that maps the ICH Q8 Design Space for each clone. #### Stage 4: Lead selection Clones and process conditions are ranked by titre, quality and robustness inside the Design Space, selecting the lead clone and its setpoints. #### Stage 5: Scale-down validation The lead conditions are confirmed in scale-down models that match pilot mixing, kLa and power-input so the DOE result transfers reliably. #### Stage 6: GMP transfer The characterised process and its Design Space are transferred to pilot and GMP bioreactors under FDA Process Validation Stage 1, de-risking the subsequent qualification batches.